Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
GRX1 encodes a member of the glutaredoxin family. Additionally we are shipping Glutaredoxin 1 Proteins (28) and Glutaredoxin 1 Kits (14) and many more products for this protein.
Showing 10 out of 47 products:
Human Monoclonal Glutaredoxin 1 Primary Antibody for IHC (p), WB - ABIN2473802
Prinarakis, Chantzoura, Thanos, Spyrou: S-glutathionylation of IRF3 regulates IRF3-CBP interaction and activation of the IFN beta pathway. in The EMBO journal 2008
AtGRXcp has a glutaredoxin/thioredoxin-like (show TXN Antibodies) fold with distinct structural features that differ from those of dithiol glutaredoxins.
Results describe the initial functional characterization of a plant monothiol Glutaredoxin and suggests a conserved biological function in protecting cells against protein oxidative damage [AtGRXcp].
Glrx ablation stabilizes HIF-1alpha (show HIF1A Antibodies) by increasing GSH adducts on Cys (show DNAJC5 Antibodies)(520) promoting in vivo HIF-1alpha (show HIF1A Antibodies) stabilization, VEGF-A (show VEGFA Antibodies) production, and revascularization in the ischemic muscles.
Prx2 (show PRRX2 Antibodies) glutathionylation is a favorable reaction that can occur in cells under oxidative stress and may have a role in redox signaling. GSH/Grx1 provide an alternative mechanism to thioredoxin (show TXN Antibodies) and thioredoxin reductase (show PRDX2 Antibodies) for Prx2 (show PRRX2 Antibodies) recycling.
The temporal relationships of Glrx1 with protein S-glutathionylation, glutathione, and cytokines/chemokines were observed as dynamic changes in lungs with allergic airway inflammation
Glutaredoxin 1 plays an important role in controlling epithelial cell responsiveness to IL-17A (show IL17A Antibodies)
Up-regulated Glrx inhibits VEGF signaling by increa (show FLT1 Antibodies)sed Flt1 causing impaired vascularization.
S-glutathionylation of Fas (show FAS Antibodies) in lung epithelium enhances epithelial apoptosis and clearance of P. aeruginosa. Glutaredoxin-1 impairs bacterial clearance and increases severity of pneumonia in association with deglutathionylation of Fas (show FAS Antibodies).
These data suggest that the overexpression of GRX1 could protect cardiomyocytes against NO-induced apoptosis, likely through the inhibition of the oxidative modification and the nuclear translocation of GAPDH (show GAPDH Antibodies).
we provide evidence that Grx1 has an important role in regulating cigarette smoke-induced lung inflammation which seems to diverge from its effects on total PSSG.
Data show that glutaredoxin acts as a reductant for methionine sulfoxide reductases A and B (MsrA (show MSR1 Antibodies) and MsrB (show MSRB2 Antibodies)) with or without resolving cysteine.
results are the first to demonstrate that Grx-1 induces angiogenesis and diminishes ventricular remodeling apparently through neovascularization mediated by Akt (show AKT1 Antibodies), VEGF (show VEGFA Antibodies), Ang-1 (show ANGPT1 Antibodies) and NF-kappaB (show NFKB1 Antibodies) as well as Bcl-2 (show BCL2 Antibodies) and survivin (show BIRC5 Antibodies)-mediated anti-apoptotic pathway
Glutaredoxin desensitizes lens to oxidative stress by connecting and integrating specific signaling and transcriptional regulation for antioxidant response.
The results demonstrate that the antiproliferative effect of NO is hampered by Trx1 (show MLL Antibodies) and Grx1 and support the strategy of weakening the thiolic antioxidant defenses when designing new antitumoral therapies.
Prx2 (show PRDX2 Antibodies) glutathionylation is a favorable reaction that can occur in cells under oxidative stress and may have a role in redox signaling. GSH/Grx1 provide an alternative mechanism to thioredoxin (show TXN Antibodies) and thioredoxin reductase (show PRDX5 Antibodies) for Prx2 (show PRDX2 Antibodies) recycling.
Glutaredoxin 1 protects human retinal pigment epithelial cells from oxidative damage by preventing AKT (show AKT1 Antibodies) glutathionylation.
A new function for GRX1 in neuronal copper homeostasis and in protection from copper-mediated oxidative injury.
Human Grx1 can catalyse reduction of Atox1 (show ATOX1 Antibodies) by glutathione but only in the presence of Cu(I).
Levels of GLRX in the cerebrospinal fluid increase significantly in the early stages of Alzheimer's disease.
Glrx overexpression increased soluble VEGF receptor (show FLT1 Antibodies) 1 (sFlt) in endothelial cells via NF-kappaB (show NFKB1 Antibodies)-dependent Wnt5a (show WNT5A Antibodies) production.
Thioredoxin 1 is inactivated due to oxidation induced by peroxiredoxin under oxidative stress and reactivated by the glutaredoxin system.
Results indicate that the activation of eNOS (show NOS3 Antibodies)/NO system is regulated by Grx 1 and coupled with inhibition of JNK (show MAPK8 Antibodies) and NF-kappaB (show NFKB1 Antibodies) signaling pathway which could alleviate the oxidative stress/apoptosis in coronary arteries endothelial cells induced by HG.
This gene encodes a member of the glutaredoxin family. The encoded protein is a cytoplasmic enzyme catalyzing the reversible reduction of glutathione-protein mixed disulfides. This enzyme highly contributes to the antioxidant defense system. It is crucial for several signalling pathways by controlling the S-glutathionylation status of signalling mediators. It is involved in beta-amyloid toxicity and Alzheimer's disease. Multiple alternatively spliced transcript variants encoding the same protein have been identified.
, glutaredoxin (thioltransferase)
, glutaredoxin (thioltransferase) pseudogene 3
, glutaredoxin (thioltransferase)-like
, glutaredoxin (grx-1)
, glutaredoxin Grx1
, glutaredoxin-1 (Grx1)
, thiol disulfide oxidoreductase
, glutaredoxin 1 (thioltransferase)